Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/39739

Title:	Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
Authors:	Drake, Marcus J MacDiarmid, Scott Chapple, Christopher R Esen, Adil Athanasiou, Stavros Cambronero Santos, Javier Mitcheson, David Herschorn, Sender Siddiqui, Emad Huang, Moses Stoelzel, Matthias View more
Mesh:	Acetanilides Adrenergic beta-3 Receptor Agonists Adult Aged Aged, 80 and over Cardiovascular Diseases Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Female Follow-Up Studies Humans Male Middle Aged Muscarinic Antagonists Single-Blind Method Solifenacin Succinate Thiazoles Treatment Outcome Urinary Bladder, Overactive View more
Issue Date:	May-2017
Citation:	Int. J. Clin. Pract..2017 May;(71)5:
Abstract:	In the BESIDE study, combination therapy (antimuscarinic [solifenacin] and β3 -adrenoceptor agonist [mirabegron]) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder (OAB) patients; however, a potential synergistic effect on the cardiovascular (CV) system requires investigation.
PMID:	28419650
URI:	https://hdl.handle.net/20.500.12530/39739
Rights:	openAccess
Appears in Collections:	Hospitales > H. U. Infanta Leonor > Artículos

Files in This Item:

File	Description	Size	Format
PMC5485167.pdf		1.03 MB	Adobe PDF	View/Open